Please assess the completion status of the following clinical trial:

Trial Title: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute symptomatic supragenual superficial vein thrombosis of the leg~* at least one of the following major risk factor for VTE:~* age \> 65 years or~* male sex or~* history of DVT/PE/SVT or~* history of cancer or active cancer or~* autoimmune disease or~* SVT of a non-varicose vein~* thrombus extension of at least 5 cm~* proximal thrombus end with more than 3 cm distance to the saphenofemoral junction (SFJ)~* age \> 18 years~* written informed consent~Exclusion Criteria:~* other indication for therapeutic anticoagulation such as acute deep vein thrombosis, acute pulmonary embolism, atrial fibrillation with indication for anticoagulant therapy~* any PE or DVT within last 6 months before inclusion~* clinical signs of PE without objective exclusion (CT or VQ scan, angiography)~* SVT without signs of thrombotic/inflammatory activity (activity signs: diameter \> 4 mm, pain, redness, elevated local or systemic temperature)~* SVT after sclerotherapy~* Duration of symptoms \> 3 weeks~* pretreatment of more than 72 h with therapeutic dosages of oral or parenteral anticoagulants~* pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants~* indication for escalated antiplatelet therapy (monotherapy with aspirin \> 325 g/d and any dual antiplatelet therapy)~* SVT closer than 3 cm to saphenofemoral junction (SVJ)~* anticipated superficial vein surgery within 90 days~* anticipated thrombolytic therapy within 90 days~* manifest clinically relevant bleeding~* clinically relevant bleeding in the last 30 days before study inclusion~* major surgery within last 30 days before inclusion~* ophthalmic, spinal or cerebral surgery within last 90 days~* severe head trauma within last 90 days~* hemorrhagic stroke within last 12 months~* hereditary or acquired severe hemorrhagic diathesis~* gastrointestinal bleeding within last 90 days requiring endoscopy~* uncontrolled arterial hypertension (systolic \> 180 mm Hg, diastolic \> 110 mm Hg)~* acute endocarditis~* low platelet count (\< 100 x 109/l)~* Prothrombin time \< 50 %~* calculated creatinine clearance \< 30 ml/min~* significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis~* life expectancy \< 3 months~* any contraindications listed for rivaroxaban or fondaparinux~* women of child bearing potential without safe contraception method~* pregnant or breastfeeding women~* participation in another trial with pharmacological intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban for 45 days oral dose: 10 mg OD
- Fondaparinux (Type: ACTIVE_COMPARATOR): Fondaparinux for 45 days subcutaneous application: 2,5 mg OD

Based on this trial design, predict the completion outcome and termination type (if applicable).